Notch | $15,000,000 | (Oct 2, 2025)
Clarifeye | $4,693,900 | (Oct 2, 2025)
Ankored | $4,000,000 | (Oct 2, 2025)
Certified by Founder
Lodge
Dispatch Bio
start up
- 24/07/2025
- Series A
- Undisclosed Amount
Established in 2022, Dispatch Bio was founded with a bold purpose: to help create a world where all cancer patients can be cured. To achieve this, the company is engineering a universal treatment across solid tumors, leveraging its first-in-class Flare platform. This novel approach combines the strengths of immunotherapy with a tumor-specific viral vector, both engineered to clear tumor cells with precision and power. Dispatch has operations in Philadelphia and San Francisco, with access to world-class researchers.
- Industry Biotechnology Research
- Website https://dispatchbio.com/
- LinkedIn https://www.linkedin.com/company/dispatch-bio/
Prosper AI | $5,000,000 | (Oct 2, 2025)
Gelt | $13,000,000 | (Oct 2, 2025)
Returnalyze | $6,000,000 | (Oct 2, 2025)
Hupside | $1,700,000 | (Oct 2, 2025)
Athernal Bio | $4,718,630 | (Oct 2, 2025)
Price.com | $12,000,000 | (Oct 2, 2025)
Mondoo | $17,500,000 | (Oct 2, 2025)
SolidCore.ai | $4,000,000 | (Oct 2, 2025)
Phaidra | $50,000,000 | (Oct 2, 2025)